Compare · DXCM vs NPCE
DXCM vs NPCE
Side-by-side comparison of DexCom Inc. (DXCM) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 54.7x NPCE ($504.9M).
- Over the past year, DXCM is down 20.1% and NPCE is up 69.0% - NPCE leads by 89.1 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 1 for NPCE).
- DXCM has more recent analyst coverage (25 ratings vs 16 for NPCE).
- Company
- DexCom Inc.
- Neuropace Inc.
- Price
- $71.54+1.52%
- $14.77+0.54%
- Market cap
- $27.61B
- $504.9M
- 1M return
- +2.57%
- -8.83%
- 1Y return
- -20.08%
- +68.99%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 16
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest NPCE
- Mizuho initiated coverage on NeuroPace with a new price target
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.64% to 52,050 units (SEC Form 4) to satisfy withholding obligation
- Director Geiger Uri was granted 789 shares, increasing direct ownership by 4% to 18,537 units (SEC Form 4)
- Director Fischer Frank M was granted 1,467 shares, increasing direct ownership by 0.25% to 599,534 units (SEC Form 4)
- Director Kumar Rakhi was granted 989 shares, increasing direct ownership by 4% to 23,039 units (SEC Form 4)
- SEC Form 8-K filed by Neuropace Inc.
- Director Huennekens R Scott was granted 2,890 shares (SEC Form 4)
- Director Fischer Frank M was granted 2,890 shares, increasing direct ownership by 0.49% to 598,067 units (SEC Form 4)
- Director Geiger Uri was granted 2,890 shares, increasing direct ownership by 19% to 17,748 units (SEC Form 4)
- Director Kumar Rakhi was granted 2,890 shares, increasing direct ownership by 15% to 22,050 units (SEC Form 4)